59356 Federal Register / Vol. 70, No.
196 / Wednesday, October 12, 2005 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 3, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–20431 Filed 10–11–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel. Research Training
in Pediatric Gastroenterology.
Date: October 26, 2005.
Time: 11 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, PhD,
Scientific Review Administrator, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 705, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–4719, guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel. Sphincter of Oddi
Dysfunction.
Date: November 1, 2005.
Time: 1:30 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Atul Sahai, PhD, Scientific
Review Administrator, Review Branch, DEA,
VerDate Aug<31>2005 19:48 Oct 11, 2005 Jkt 208001
NIDDK, National Institues of Health, Room
772, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–2242,
sahaia@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 02, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–20432 Filed 10–11–05; 8:45am]
BILLING CODE Code 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Board of Scientific
Counselors, National Library of
Medicine, October 25, 2005, 9 a.m. to
October 25, 2005, 5 p.m., National
Library of Medicine, Building 38, Board
Room, 2nd Floor, 8600 Rockville Pike,
Bethesda, MD 20892 which was
published in the Federal Register on
August 16, 2005, 70 FR 48166.
In addition to the October 25, 2005
meeting, there will be a meeting on
October 24, 2005 from 5 p.m. to 7 p.m.
at the Bethesda Marriott, 5151 Pooks
Hill Road, Bethesda, Maryland 20892.
The meeting is partially closed to the
public.
Dated: October 3, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–20430 Filed 10–11–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
AGENCY: Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\12OCN1.SGM
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at http://workplace.samhsa.gov
and http://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs,
SAMHSA/CSAP, Room 2–1035, 1 Choke
Cherry Road, Rockville, Maryland
20857; (240) 276–2600 (voice), (240)
276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
12OCN1
 Federal Register / Vol. 70, No. 196 / Wednesday, October 12, 2005 / Notices 59357

standards to conduct drug and specimen 608–267–6225. MedTox Laboratories, Inc.

validity tests on urine specimens: LabOne, Inc. 402 W. County Road D
ACL Laboratories 10101 Renner Blvd. St. Paul, MN 55112
8901 W. Lincoln Ave. Lenexa, KS 66219 651–636–7466 / 800–832–3244.
West Allis, WI 53227 913–888–3927/800–873–8845 MetroLab-Legacy Laboratory Services
414–328–7840/800–877–7016 (Formerly: Center for Laboratory 1225 NE 2nd Ave.
(Formerly: Bayshore Clinical Services, a Division of LabOne, Inc.). Portland, OR 97232
Laboratory). Laboratory Corporation of America 503–413–5295 / 800–950–5295.
ACM Medical Laboratory, Inc. Holdings Minneapolis Veterans Affairs Medical
160 Elmgrove Park 7207 N. Gessner Road Center
Rochester, NY 14624 Houston, TX 77040 Forensic Toxicology Laboratory
585–429–2264. 713–856–8288/800–800–2387. 1 Veterans Drive
Advanced Toxicology Network Laboratory Corporation of America Minneapolis, MN 55417
3560 Air Center Cove, Suite 101 Holdings 612–725–2088.
Memphis, TN 38118 69 First Ave. National Toxicology Laboratories, Inc.
901–794–5770/888–290–1150. Raritan, NJ 08869
1100 California Ave.
908–526–2400/800–437–4986
Aegis Analytical Laboratories, Inc. (Formerly: Roche Biomedical Bakersfield, CA 93304
345 Hill Ave. Laboratories, Inc.). 661–322–4250 / 800–350–3515.
Nashville, TN 37210 Northwest Toxicology, a LabOne
615–255–2400. Laboratory Corporation of America
Holdings Company
Baptist Medical Center-Toxicology 2282 South Presidents Drive, Suite C
1904 Alexander Drive
Laboratory West Valley City, UT 84120
Research Triangle Park, NC 27709
9601 I–630, Exit 7 801–606–6301 / 800–322–3361
919–572–6900/800–833–3984
Little Rock, AR 72205–7299 (Formerly: LabCorp Occupational (Formerly: LabOne, Inc., dba Northwest
501–202–2783 Testing Services, Inc., CompuChem Toxicology; NWT Drug Testing,
(Formerly: Forensic Toxicology NorthWest Toxicology, Inc.;
Laboratories, Inc.; CompuChem
Laboratory Baptist Medical Center). Northwest Drug Testing, a division of
Laboratories, Inc., A Subsidiary of
Clinical Reference Lab Roche Biomedical Laboratory; Roche NWT Inc.).
8433 Quivira Road CompuChem Laboratories, Inc., A One Source Toxicology Laboratory, Inc.
Lenexa, KS 66215–2802 Member of the Roche Group). 1213 Genoa-Red Bluff
800–445–6917. Pasadena, TX 77504
Laboratory Corporation of America
Diagnostic Services, Inc., dba DSI Holdings 888–747–3774
12700 Westlinks Drive 10788 Roselle St. (Formerly: University of Texas Medical
Fort Myers, FL 33913 San Diego, CA 92121 Branch, Clinical Chemistry Division;
239–561–8200/800–735–5416. 800–882–7272 UTMB Pathology-Toxicology
Doctors Laboratory, Inc. (Formerly: Poisonlab, Inc.). Laboratory).
2906 Julia Drive Laboratory Corporation of America Oregon Medical Laboratories
Valdosta, GA 31602 Holdings P.O. Box 972
229–671–2281. 550 17th Ave., Suite 300 722 East 11th Ave.
DrugScan, Inc. Seattle, WA 98122 Eugene, OR 97440–0972
P.O. Box 2969 206–923–7020 / 800–898–0180 541–687–2134.
1119 Mearns Road (Formerly: DrugProof, Division of Pacific Toxicology Laboratories
Warminster, PA 18974 Dynacare/Laboratory of Pathology, 9348 DeSoto Ave.
215–674–9310. LLC; Laboratory of Pathology of Chatsworth, CA 91311
Dynacare Kasper Medical Laboratories* Seattle, Inc.; DrugProof, Division of 800–328–6942
10150–102 St., Suite 200 Laboratory of Pathology of Seattle, (Formerly: Centinela Hospital Airport
Edmonton, Alberta Inc.). Toxicology Laboratory).
Canada T5J 5E2 Laboratory Corporation of America Pathology Associates Medical
780–451–3702/800–661–9876. Holdings Laboratories
ElSohly Laboratories, Inc. 1120 Main Street 110 West Cliff Dr.
5 Industrial Park Drive Southaven, MS 38671 Spokane, WA 99204
Oxford, MS 38655 866–827–8042 / 800–233–6339 509–755–8991 / 800–541–7897x7.
(Formerly: LabCorp Occupational
662–236–2609. Physicians Reference Laboratory
Testing Services, Inc.; MedExpress/
Express Analytical Labs National Laboratory Center). 7800 West 110th St.
3405 7th Ave., Suite 106 Overland Park, KS 66210
Marshfield Laboratories
Marion, IA 52302 913–339–0372 / 800–821–3627.
Forensic Toxicology Laboratory
319–377–0500. 1000 North Oak Ave. Quest Diagnostics Incorporated
Gamma-Dynacare Medical Laboratories* Marshfield, WI 54449 3175 Presidential Dr.
A Division of the Gamma-Dynacare 715–389–3734 / 800–331–3734. Atlanta, GA 30340
Laboratory Partnership MAXXAM Analytics Inc.* 770–452–1590 / 800–729–6432
245 Pall Mall Street 6740 Campobello Road (Formerly: SmithKline Beecham
London, ONT, Canada N6A 1P4 Mississauga, ON Clinical Laboratories; SmithKline Bio-
519–679–1630. Canada L5N 2L8 Science Laboratories).
General Medical Laboratories 905–817–5700 Quest Diagnostics Incorporated
36 South Brooks St. (Formerly: NOVAMANN (Ontario), 4770 Regent Blvd.
Madison, WI 53715 Inc.). Irving, TX 75063

VerDate Aug<31>2005 19:48 Oct 11, 2005 Jkt 208001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\12OCN1.SGM 12OCN1
 59358 Federal Register / Vol. 70, No. 196 / Wednesday, October 12, 2005 / Notices
800–824–6152
(Moved from the Dallas location on
03/31/01; Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated
4230 South Burnham Ave., Suite 250
Las Vegas, NV 89119–5412
702–733–7866 / 800–433–2750
(Formerly: Associated Pathologists
Laboratories, Inc.).
Quest Diagnostics Incorporated
400 Egypt Road
Norristown, PA 19403
610–631–4600 / 877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-
Science Laboratories).
Quest Diagnostics Incorporated
506 E. State Pkwy.
Schaumburg, IL 60173
800–669–6995 / 847–885–2010
(Formerly: SmithKline Beecham
Clinical Laboratories; International
Toxicology Laboratories).
Quest Diagnostics Incorporated
7600 Tyrone Ave.
Van Nuys, CA 91405
818–989–2520 / 800–877–2520
(Formerly: SmithKline Beecham
Clinical Laboratories).
Scientific Testing Laboratories, Inc.
450 Southlake Blvd.
Richmond, VA 23236
804–378–9130.
Sciteck Clinical Laboratories, Inc.
317 Rutledge Road
Fletcher, NC 28732
828–650–0409
S.E.D. Medical Laboratories
5601 Office Blvd.
Albuquerque, NM 87109
505–727–6300 / 800–999–5227.
South Bend Medical Foundation, Inc.
530 N. Lafayette Blvd.
South Bend, IN 46601
574–234–4176 x276.
Southwest Laboratories
4645 E. Cotton Center Boulevard
Suite 177
Phoenix, AZ 85040
602–438–8507 / 800–279–0027.
Sparrow Health System
Toxicology Testing Center, St. Lawrence
Campus
1210 W. Saginaw
Lansing, MI 48915
517–364–7400
* The Standards Council of Canada (SCC) voted
to end its Laboratory Accreditation Program for
Substance Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that program were
accredited to conduct forensic urine drug testing as
required by U.S. Department of Transportation
(DOT) regulations. As of that date, the certification
of those accredited Canadian laboratories will
continue under DOT authority. The responsibility
for conducting quarterly performance testing plus
VerDate Aug<31>2005 19:48 Oct 11, 2005 Jkt 208001
(Formerly: St. Lawrence Hospital &
Healthcare System).
St. Anthony Hospital Toxicology
Laboratory
1000 N. Lee St.
Oklahoma City, OK 73101
405–272–7052.
Toxicology & Drug Monitoring
Laboratory
University of Missouri Hospital &
Clinics
301 Business Loop 70 West, Suite 208
Columbia, MO 65203
573–882–1273.
Toxicology Testing Service, Inc.
5426 N.W. 79th Ave.
Miami, FL 33166
305–593–2260.
US Army Forensic Toxicology Drug
Testing Laboratory
2490 Wilson St.
Fort George G. Meade, MD 20755–5235
301–677–7085.
As a result of hurricane Katrina, the
following laboratory’s certification is
suspended because extensive damage to
the New Orleans area has prevented the
laboratory from testing specimens and
fully participating in the National
Laboratory Certification Program:
Kroll Laboratory Specialists, Inc.
1111 Newton St.
Gretna, LA 70053
504–361–8989 / 800–433–3823
(Formerly: Laboratory Specialists, Inc.).
Anna Marsh,
Director, Office Program Services, SAMHSA.
[FR Doc. 05–20488 Filed 10–11–05; 8:45 am]
BILLING CODE 4160–20–U
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
Agency Information Collection
Activities: Proposed Collection;
Comment Request
AGENCY: Federal Emergency
Management Agency, Emergency
Preparedness and Response Directorate,
U.S. Department of Homeland Security.
ACTION: Notice and request for
comments.
periodic on-site inspections of those LAPSA-
accredited laboratories was transferred to the U.S.
HHS, with the HHS’ NLCP contractor continuing to
have an active role in the performance testing and
laboratory inspection processes. Other Canadian
laboratories wishing to be considered for the NLCP
may apply directly to the NLCP contractor just as
U.S. laboratories do.
Upon finding a Canadian laboratory to be
qualified, HHS will recommend that DOT certify
PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\12OCN1.SGM
SUMMARY: The Federal Emergency
Management Agency, as part of its
continuing effort to reduce paperwork
and respondent burden, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed continuing
information collections. In accordance
with the Paperwork Reduction Act of
1995 (44 U.S.C. 3506(c)(2)(A)), this
notice seeks comments concerning the
application for participation in the
National Flood Insurance Program
(NFIP).
SUPPLEMENTARY INFORMATION: The NFIP
is authorized by Public Law 90–448
(1968) and expanded by Public Law 93–
234 (1973). Communities must make
application for eligibility in the program
by submitting the items listed on the
enclosed ‘‘prerequisites for the sale of
flood insurance’’ which is taken from
section 59.22 CFR 44 of the NFIP
regulations. Section 201 of the Flood
Disaster Protection Act of 1973 requires
all flood-prone communities throughout
the country to apply for participation
one year after their flood prone
identification or submit to the
prohibition of certain types of Federal
and Federally-related financial
assistance for use in their floodplains.
Collection of Information
Title: Application for Participation in
the National Flood Insurance Program.
Type of Information Collection:
Reinstatement.
OMB Number: 1660–0004.
Form Numbers: FEMA Form 81–64.
Abstract: The NFIP provides flood
insurance to communities that apply for
participation and make a commitment
to adopt and enforce land use control
measures that are designed to protect
development from future flood damages.
The application form will enable FEMA
to continue to rapidly process new
community applications and to thereby
more quickly provide flood insurance
protection to the residents of the
communities. Participation in the NFIP
is mandatory in order for flood related
Presidentially-declared communities to
receive Federal disaster assistance.
Affected Public: State, Local or Tribal
Governments.
Estimated Total Annual Burden
Hours: 600 hours.
the laboratory (Federal Register, July 16, 1996) as
meeting the minimum standards of the Mandatory
Guidelines published in the Federal Register on
April 13, 2004 (69 FR 19644). After receiving DOT
certification, the laboratory will be included in the
monthly list of HHS-certified laboratories and
participate in the NLCP certification maintenance
program.
12OCN1